Pharmacogenomics: The Future of Personalized Medicine

The Promise of Pharmacogenomics

One of medicine's most persistent frustrations is that the same medication at the same dose produces vastly different responses in different patients. One patient on warfarin may achieve therapeutic anticoagulation at 5 mg/day; another requires 50 mg/day. One patient on codeine experiences dangerous respiratory depression; another gets virtually no pain relief. One patient on clopidogrel has normal platelet inhibition; another — carrying a CYP2C19 loss-of-function allele — gets no protection from stents.

Pharmacogenomics (PGx) studies how genetic variations affect medicine response — offering the potential to predict the right medicine and right dose for each individual before treatment begins, rather than discovering the hard way through adverse events or treatment failure.

---

Foundational Concepts

#

Pharmacokinetic Pharmacogenomics (PK)

Genetic variants in medicine-metabolizing enzymes, transporters, and receptors alter how medicines are absorbed, distributed, metabolized, and eliminated.

Metabolizer phenotypes (for CYP enzymes):

Poor metabolizer (PM): Loss-of-function variants on both alleles; medicine accumulates → toxicity with standard doses; prodrugs fail to activate

Intermediate metabolizer (IM): One functional, one reduced-function allele; intermediate metabolism

Normal/Extensive metabolizer (NM/EM): Standard phenotype; expected response

Rapid/Ultrarapid metabolizer (UM): Extra gene copies or gain-of-function variants; medicine metabolized too quickly → subtherapeutic levels; prodrugs over-activated

#

Pharmacodynamic Pharmacogenomics (PD)

Genetic variants in medicine targets (receptors, channels, enzymes) alter medicine effect independent of blood levels.

---

Key Pharmacogenomic Genes and Their Medicine Impacts

#

CYP2D6 — "The Workhorse"

Metabolizes ~25% of all medicines. Enormous genetic variation — 100+ known alleles.

Critical medicine interactions:

Codeine → Morphine (prodrug activation): CYP2D6 converts codeine to morphine. UMs convert too much → morphine toxicity → respiratory depression → deaths in children (FDA Black Box Warning for children under 12; contraindicated in breastfeeding mothers). PMs get no pain relief (no conversion).

Tamoxifen → Endoxifen (prodrug activation): PM/IM status significantly reduces tamoxifen efficacy in breast cancer — potentially increasing mortality. CYP2D6 testing before tamoxifen is debated but increasingly recommended.

Tricyclic antidepressants, SSRIs: Wide dose variability based on CYP2D6 status

Antipsychotics (risperidone, haloperidol, aripiprazole): Significant plasma level variation

#

CYP2C19 — "The Antiplatelet Gene"

Metabolizes clopidogrel (prodrug), PPIs, escitalopram, antifungals.

Critical medicine interactions:

Clopidogrel (Plavix): CYP2C19 activates clopidogrel to its active antiplatelet metabolite. PM/IM patients (~30% of Asians, ~25% of Blacks, ~15% of Whites) have inadequate platelet inhibition → increased risk of stent thrombosis, heart attack after coronary intervention. FDA Black Box Warning since 2010. CYP2C19 testing recommended; prasugrel or ticagrelor used as alternatives in PMs.

PPIs (omeprazole, esomeprazole): UMs metabolize PPIs rapidly → may need higher doses for acid suppression; IMs/PMs get prolonged acid suppression

Antidepressants (escitalopram, citalopram): PM/IM status increases medicine exposure — dose reduction recommended

#

CYP2C9 — "The Warfarin Gene"

Warfarin: CYP2C9 metabolizes S-warfarin (more potent isomer). *2 and *3 alleles reduce enzyme activity → warfarin accumulates → bleeding risk. Combined with VKORC1 variants (the warfarin target enzyme), PGx testing can explain 30-50% of warfarin dose variation. FDA-approved warfarin dosing algorithms incorporate CYP2C9 and VKORC1 genotypes.

NSAIDs (celecoxib, diclofenac, ibuprofen): Accumulation in PMs

#

TPMT/NUDT15 — "The Thiopurine Gene"

Azathioprine/6-mercaptopurine (thiopurines): Used in leukemia, IBD, transplant rejection. TPMT or NUDT15 PM phenotype → severe, potentially fatal myelosuppression at standard doses. FDA recommends TPMT/NUDT15 testing before initiating thiopurines. Guidelines recommend 10-fold dose reduction in PMs.

#

HLA Alleles — Immunogenicity

HLA-B*5701 → Abacavir hypersensitivity: Potentially fatal hypersensitivity in 5-8% of carriers. Prospective testing eliminates this reaction. FDA requires testing before initiating abacavir.

HLA-B*1502 → Carbamazepine-induced Stevens-Johnson Syndrome/TEN: Present in ~8% of Han Chinese. FDA requires testing in patients of Asian descent before starting carbamazepine.

HLA-A*3101 → Carbamazepine hypersensitivity: In European patients

---

Current PGx Testing in Clinical Practice

How testing works:

Buccal swab (cheek swab) or blood sample

Panel tests 25-50+ genes simultaneously

Results include phenotype predictions for dozens of medicine-gene pairs

Results are typically lifelong (germline genetics don't change)

Major platforms:

GeneSight (Myriad Genetics) — focused on psychiatric medications

Genomind — psychiatric/neurological medications

Coriell Life Sciences — comprehensive PGx

Invitae, Tempus — broader genetic panels including PGx

Cost: $250-500 for comprehensive panels. Insurance coverage improving but inconsistent.

CPIC Guidelines: Clinical Pharmacogenomics Implementation Consortium provides free, peer-reviewed, evidence-based medicine dosing guidelines for genetic variants. cpicpgx.org